Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Payers Want Deep Discounts To Make Biosimilars Worth Their While

Executive Summary

Interviews with US payers suggest that some expect discounts of 40%-50% off prices of branded drugs and that many insurers are more focused on promoting use of biosimilars in new starts, rather than switching stable patients.

Advertisement

Related Content

2017 – Scrip Readers’ Pharma Year In Review
2017 – Scrip Readers’ Pharma Year In Review
Biosimilars: Sandoz Pegfilgrastim Review, Amgen Adalimumab Launch Extended To 2018
UnitedHealthcare Prefers Basaglar Biosimilar At Lantus' Expense

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC098402

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel